Ovarian hypercalcemia type small cell cancer cell line and use thereof

By establishing and providing the ovarian hypercalcemia-type small cell carcinoma cell line SCCOHT-CH-1, the problem of lack of cell research tools in Chinese patients has been solved, the disease mechanism research and the development of new therapeutic drugs has been promoted, and effective for Chinese patients Treatment plan.

CN115786261BActive Publication Date: 2024-12-06THE OBSTETRICS & GYNECOLOGY HOSPITAL OF FUDAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211506062.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-28
Publication Date
2024-12-06
Estimated Expiration
2042-11-28

AI Technical Summary

Technical Problem

There is a lack of research tool cells for Chinese patients with ovarian hypercalcemia type small cell carcinoma in the prior art, resulting in insufficient research on tumor characteristics and drug sensitivity, and a lack of effective treatment plans for Chinese patients.

Method used

Establish and provide a ovarian hypercalcemia-type small cell carcinoma cell line SCCOHT-CH-1 and its asexual reproductive progeny cells from Chinese patients. It is used as a research platform for studying the mechanism of disease occurrence, drug action mechanism and Target development, providing animal models for drug screening and therapeutic product development.

Benefits of technology

Provides a research platform for patients with ovarian hypercalcemia type small cell carcinoma in China, promotes disease mechanism research and the development of new therapeutic drugs, fills the gap in the lack of research tool cells in the existing technology, and improves the treatment of Chinese patients. Solution R&D efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003968169850000061
    Figure BDA0003968169850000061
  • Figure BDA0003968169850000071
    Figure BDA0003968169850000071
  • Figure HDA0003968169860000011
    Figure HDA0003968169860000011
Patent Text Reader

Abstract

The present invention relates to the field of cell engineering, and in particular to a human ovarian hypercalcemia-type small cell carcinoma primary tumor cell line SCCOHT-CH-1 and its use. The SCCOHT-CH-1 described in the present invention provides a research platform to further study ovarian hypercalcemia-type small cell carcinoma in Chinese SCCOHT patients. As a research platform, SCCOHT-CH-1 cells have the following uses: 1. Basic research: (1) Disease pathogenesis of ovarian hypercalcemia-type small cell carcinoma; (2) Gene function related to ovarian hypercalcemia-type small cell carcinoma; (3) Mechanism of action of drugs related to ovarian hypercalcemia-type small cell carcinoma; 2. Development of disease diagnosis products and therapeutic products: Through basic research, the molecular mechanism of the onset of SCCOHT is further clarified, and new therapeutic targets are discovered through the tissue pathogenesis mechanism, which is convenient for drug research and development, such as chemical synthesis drug efficacy research, and screening and identification of effective ingredients of traditional Chinese medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of cell engineering, in particular to a human ovarian hypercalcemia type small cell cancer cell line and a use thereof. Background Art

[0002] Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare gynecological tumor that originates from the ovary and is highly malignant and has a very poor prognosis. So far, no more than 500 cases have been reported worldwide. SCCOHT is common in young women (14 months to 58 years old, with a median age of 24 years). This tumor is prone to recurrence and has a poor prognosis. The one-year survival rate of patients is only 50%, and the five-year survival rate is less than 10%.

[0003] Although the malignant origin of SCCOHT is still unclear and it is difficult to distinguish it from other small cell tumors occurring in the ovary in terms of tissue morphology, there have been some breakthroughs in its molecular pathogenesis. High-throughput sequencing of SCCOHT tumor tissues found that more than 90% of patients carry systemic or germline SMARCA4 (SWI / SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4) gene mutations, and the SMARCA4 protein (or BRG1 protein, BRM / SWI2-related gene 1) encoded by it is missing in SCCOHT tumor tissues, which is also an important indicator for the diagnosis of SCCOHT. At the same time, unlike other types of tumors with aneuploid / polyploid chromosomes, the chromosome ploidy of SCCOHT tumor cells is mostly diploid.

[0004] Due to the rarity of SCCOHT, randomized controlled clinical trials are difficult to conduct, and there is currently no standard treatment plan. In addition, SCCOHT is extremely malignant and has a very poor prognosis. The development of new therapeutic drugs has become an urgent problem to be solved in the clinical treatment of SCCOHT. Scientific research has found that the current potential therapeutic drugs for SCCOHT mainly include: ① epigenetic treatment, such as EZH2 inhibitors, histone deacetylase (HDAC) inhibitors, and lysine-specific histone demethylase 1 (LSD1) inhibitors; ② kinase inhibitors, such as tyrosine kinase (RTK) inhibitors and CDK4 / 6 inhibitors; ③ immunotherapy, PD-1 monoclonal antibody. Generally speaking, the development of new drugs first requires the proof of basic experiments, and then clinical trials for patients. The most classic test subjects for basic experiments are cell lines and model animals. At present, there are only three SCCOHT-derived tumor cell lines available for scientific research in the world, namely: (1) BIN-67 cells (Dana-Farber Cancer Institute, Boston, Massachusetts, USA): isolated from the trypsin digest of primary ovarian small cell carcinoma metastatic pelvic nodules; (2) SCCOHT-1 cells (Germany): derived from the original SCCOHT recurred after treatment; (3) COV434 cells (Netherlands): originally described as a cell line derived from granulosa cell tumor, recently revised as a SCCOHT cell line due to the discovery of SMARCA4 gene mutations and the clinical characteristics of the patients from which the cell line was derived. All three SCCOHT cell lines are from Western countries, and the potential therapeutic drugs mentioned above are also based on experimental data from Western patients. People of different races have different genetic backgrounds and may respond differently to the same drug. At present, there are very few studies on the tumor characteristics and drug sensitivity of Chinese SCCOHT patients, largely due to the lack of research tool cells. Therefore, it is urgent to establish SCCOHT cell lines from Chinese patients for the study of the pathogenesis of Chinese SCCOHT patients and the development of targeted drugs. Summary of the invention

[0005] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide an ovarian hypercalcemia type small cell carcinoma cell line and its use, so as to solve the problem that there are few studies on tumor characteristics and drug sensitivity of Chinese ovarian hypercalcemia type small cell carcinoma patients in the prior art, and there is a lack of tool cells for research.

[0006] To achieve the above-mentioned purpose and other related purposes, the present invention provides an ovarian hypercalcemia type small cell carcinoma cell line and its asexually propagated progeny cells and uses thereof. The ovarian hypercalcemia type small cell carcinoma (SCCOHT) cell line is deposited in the General Microbiology Center of China Microorganism Culture Collection Administration CGMCC, the cell line name is human ovarian hypercalcemia type small cell carcinoma primary tumor cell line SCCOHT-CH-1, the preservation date is 2022-08-18, the preservation number is CGMCC No.45243, and the preservation address is Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.

[0007] The ovarian hypercalcemia type small cell carcinoma cell line SCCOHT-CH-1 is derived from a human tumor recurrence focus.

[0008] Preferably, the identification marker of the ovarian hypercalcemia small cell carcinoma cell line SCCOHT-CH-1 is the SMARCA4 gene or protein.

[0009] The ovarian hypercalcemia type small cell carcinoma cell line SCCOHT-CH-1 is a diploid karyotype.

[0010] The present invention also provides a method for establishing an ovarian hypercalcemia type small cell cancer cell line SCCOHT-CH-1.

[0011] The present invention also provides the ovarian hypercalcemia type small cell carcinoma animal model.

[0012] The present invention also provides a method for constructing the ovarian hypercalcemia-type small cell carcinoma animal model.

[0013] The present invention also provides the use of the ovarian hypercalcemia type small cell cancer cell line SCCOHT-CH-1 or the ovarian hypercalcemia type small cell cancer animal model in developing tumor treatment product targets, in screening tumor treatment products, and in preparing tumor treatment products.

[0014] The present invention also provides the use of the ovarian hypercalcemia type small cell cancer cell line SCCOHT-CH-1 or the ovarian hypercalcemia type small cell cancer animal model in the screening of biomarkers of ovarian hypercalcemia type small cell cancer or the study of the occurrence and development mechanism of ovarian hypercalcemia type small cell cancer.

[0015] As described above, the ovarian hypercalcemia small cell cancer cell line and its use of the present invention have the following beneficial effects:

[0016] SCCOHT-CH-1 cells provide a research platform for studying SCCOHT, a rare disease, and further studying ovarian hypercalcemic small cell carcinoma in Chinese SCCOHT patients. As a research platform, SCCOHT-CH-1 cells have the following uses:

[0017] 1. Basic research

[0018] (1) The pathogenesis of ovarian hypercalcemic small cell carcinoma;

[0019] (2) Gene functions associated with ovarian hypercalcemic small cell carcinoma;

[0020] (3) Mechanism of action of drugs related to hypercalcemic ovarian small cell carcinoma.

[0021] 2. Disease diagnosis and treatment

[0022] Through basic research, the molecular mechanism of SCCOHT is further clarified, and new therapeutic targets are discovered through tissue pathogenesis, which is convenient for drug research and development, such as the efficacy research of chemical synthetic drugs, the screening and identification of effective ingredients of traditional Chinese medicine, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the primary cell culture result of the ovarian hypercalcemia small cell carcinoma cell line SCCOHT-CH-1 in the present invention.

[0024] Figure 2 This is the result of chromosome karyotype analysis of the ovarian hypercalcemia small cell carcinoma cell line SCCOHT-CH-1 in the present invention.

[0025] Figure 3 This is the result of identifying two pathogenic variants of SMARCA4 gene mutations in the ovarian hypercalcemia small cell carcinoma cell line SCCOHT-CH-1 in the present invention.

[0026] Figure 4 This is the expression verification result of the characteristic protein of SCCOHT tumor in the present invention.

[0027] Figure 5 This is the animal model of the ovarian hypercalcemia small cell carcinoma cell line SCCOHT-CH-1 in the present invention.

[0028] Figure 6 This is the result of in vitro screening of drugs in the ovarian hypercalcemia type small cell carcinoma cell line SCCOHT-CH-1 in the present invention. DETAILED DESCRIPTION

[0029] The present invention provides an ovarian hypercalcemic type small cell carcinoma cell line and asexually propagated progeny cells thereof. The ovarian hypercalcemic type small cell carcinoma (SCCOHT) cell line is deposited in the General Microbiology Center of China Microorganism Culture Collection Committee CGMCC, the cell line is named human ovarian hypercalcemic type small cell carcinoma primary tumor cell line SCCOHT-CH-1, the preservation date is 2022-08-18, the preservation number is CGMCC No.45243, and the preservation address is Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.

[0030] The ovarian hypercalcemia type small cell carcinoma cell line SCCOHT-CH-1 is derived from a human tumor recurrence focus.

[0031] The identification marker of the ovarian hypercalcemia type small cell carcinoma cell line SCCOHT-CH-1 is a short tandem repeat (STR) site.

[0032] Furthermore, the short tandem repeat sequence site is selected from one or more of AMEL, D5S818, TH01, TPOX, FGA, D13S317, D18S51, CSF1PO, D16S539, D19S433, D21S11, D8S1179, D2S1338, D7S820, VWA, and D3S1358.

[0033] The identification marker of the ovarian hypercalcemia type small cell carcinoma cell line SCCOHT-CH-1 is also SMARCA4 gene or protein.

[0034] The ovarian hypercalcemia type small cell carcinoma cell line SCCOHT-CH-1 is a diploid karyotype.

[0035] The ovarian hypercalcemia-type small cell carcinoma cell line SCCOHT-CH-1 of the present invention is used for non-therapeutic and / or non-diagnostic purposes.

[0036] The present invention also provides a method for establishing an ovarian hypercalcemia-type small cell carcinoma cell line SCCOHT-CH-1, the method comprising the following steps:

[0037] 1) Tissues obtained from tumor recurrence foci of SCCOHT patients were processed into tissue fragments after the connective tissue and necrotic tissue were removed;

[0038] 2) culturing the above tissue fragments;

[0039] 3) Screening and obtaining the ovarian hypercalcemia-type small cell carcinoma cell line SCCOHT-CH-1.

[0040] In some embodiments, the tissue obtained from the tumor recurrence focus in step 1) is soaked in sterile Hanks solution, washed, and then the connective tissue and necrotic tissue are removed. Preferably, the volume of the tissue obtained from the tumor recurrence focus is 0.8-1.2 cm 3 .

[0041] In some embodiments, the size of the tissue fragments in step 1) is 0.8-1.2 mm 3 .

[0042] In some embodiments, the screening method in step 3) is selected from one or more of mechanical scraping, repeated adhesion, digestion exclusion or collagenase digestion. Preferably, the screening method is repeated adhesion.

[0043] Furthermore, the repeated adhesion method comprises the following steps:

[0044] 1a) Prepare cell suspension after 0.25% trypsin digestion;

[0045] 1b) leaving the cells in step 1a) to stand for 15-20 minutes until some cells in the cell suspension adhere to the wall;

[0046] 1c) continuing to culture the cell suspension in step 1b);

[0047] 1d) Repeat step 1a), step 1b) and step 1c) 3-5 times to obtain purified ovarian hypercalcemia-type small cell carcinoma cells.

[0048] In some embodiments, the culture medium of the ovarian hypercalcemic small cell carcinoma cells comprises one or more of RPMI-1640, serum, sodium pyruvate, L-glutamine, 4-hydroxyethylpiperazineethanesulfonic acid, or antibiotics.

[0049] The present invention also provides the ovarian hypercalcemia type small cell carcinoma animal model, wherein the ovarian hypercalcemia type small cell carcinoma cell line SCCOHT-CH-1 is transplanted in the ovarian hypercalcemia type small cell carcinoma animal model. Preferably, the ovarian hypercalcemia type small cell carcinoma animal model is a mouse model.

[0050] The present invention also provides a method for constructing the ovarian hypercalcemia type small cell carcinoma animal model, which comprises inoculating ovarian hypercalcemia type small cell carcinoma cells cultured in vitro into the back of mice.

[0051] In some embodiments, the number of cells inoculated with ovarian hypercalcemia small cell cancer cells is 0.8-1.2×10 7 indivual.

[0052] In one specific embodiment, the mouse is a nude mouse.

[0053] The animal model of ovarian hypercalcemia-type small cell carcinoma is a BALB / c Nude mouse model.

[0054] The present invention also provides the use of the ovarian hypercalcemia type small cell carcinoma cell line SCCOHT-CH-1 or the ovarian hypercalcemia type small cell carcinoma animal model in developing tumor treatment product targets, screening tumor treatment products, or preparing tumor treatment products. Preferably, the tumor is ovarian hypercalcemia type small cell carcinoma.

[0055] The tumor treatment product is selected from drugs. The use is, for example, to study the drug metabolism, efficacy or safety of treating ovarian hypercalcemia type small cell carcinoma using the ovarian hypercalcemia type small cell carcinoma cell line SCCOHT-CH-1 or an animal model. Another example is to screen drugs for treating ovarian hypercalcemia type small cell carcinoma using the ovarian hypercalcemia type small cell carcinoma cell line SCCOHT-CH-1 or an animal model.

[0056] In some specific embodiments, the drug is selected from one or more of ponatinib, palbociclib, ribociclib, abemaciclib, dacarbazine, carboplatin, erlotinib, vemurafenib, dabrafenib, cobimetinib, trametinib, cisplatin, paclitaxel, pembrolizumab or lenvatinib.

[0057] The present invention also provides the use of the ovarian hypercalcemia type small cell cancer cell line SCCOHT-CH-1 or the ovarian hypercalcemia type small cell cancer animal model in the screening of biomarkers for ovarian hypercalcemia type small cell cancer or the study of the occurrence and development mechanism of ovarian hypercalcemia type small cell cancer. The mechanism study is a study conducted in vitro.

[0058] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0059] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.

[0060] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0061] Example 1 SCCOHT-CH-1 primary cell culture and establishment

[0062] The primary cells in this patent application come from a tumor recurrence lesion of a SCCOHT patient who underwent surgery at the Obstetrics and Gynecology Hospital Affiliated to Fudan University in October 2021. Take 1 cm of fresh surgically removed tumor tissue 3 Immerse in sterile Hanks solution to clean, remove connective tissue and necrotic tissue, and cut into about 1mm 3 Small pieces of different sizes. Inoculate the tissue blocks evenly on the wall of a T25 culture flask, let it stand and culture. Change the medium once every 3 days with half the volume. Observe about 1 week after inoculation until the cells grow out of the tissue blocks. Pass the first generation about 2 weeks after inoculation, digest with 0.25% trypsin, inoculate the cell suspension in a culture flask (the culture medium does not contain serum) and let it stand for 15 to 20 minutes. Observe under an inverted phase contrast microscope. If some cells are attached to the wall, pour the cell suspension into another culture flask and continue to culture. Repeat the above method for the next passaging. Repeat 3 to 5 times to completely separate tumor cells from fibroblasts.

[0063] When the cells covered the bottom of the bottle, remove the old culture medium in the original bottle, rinse once with PBS buffer, digest with 0.25% trypsin, and pass the cells at a ratio of 1:3. So far, more than 30 generations have been passed. Figure 1 The conventional in vitro culture conditions were RPMI-1640 cell culture medium containing 15% FBS, 1% sodium pyruvate, 1% L-glutamine, 1% HEPES and 1% triple antibody, and cultured in an incubator at 37°C and 5% CO2 volume fraction.

[0064] Example 2 Identification of short tandem repeat sequences in SCCOHT-CH-1 primary cells

[0065] DNA from SCCOHT-CH-1 cells and SCCOHT tumor tissues was extracted using the Axygen-DNA extraction kit and amplified by PCR. A total of 16 loci (including sex genes) were selected: AMEL, D5S818, TH01, TPOX, FGA, D13S317, D18S51, CSF1PO, D16S539, D19S433, D21S11, D8S1179, D2S1338, D7S820, VWA, and D3S1358. The STR loci were detected using an ABI 3730XL genetic analyzer. The results are as follows:

[0066]

[0067]

[0068] Example 3 Analysis of chromosome karyotype of SCCOHT-CH-1 cell line

[0069] Take cells in logarithmic growth phase, treat with 0.25μg / mL colchicine for 6h, and incubate at 37℃ overnight. Collect metaphase cells, fix with methanol-glacial acetic acid (3:1). After trypsin digestion, stain with Giemsa stain, observe and count under a microscope. Select the well-dispersed and moderately stained mitotic phase for karyotype analysis. The analysis result is 46, XX, diploid karyotype, such as Figure 2 .

[0070] Example 4 Second generation sequencing and Sanger verification

[0071] Next-generation sequencing (NGS), also known as high-throughput sequencing, is a DNA sequencing technology developed based on PCR and gene chips. During the DNA replication process, next-generation sequencing determines the DNA sequence by capturing the special markers (usually fluorescent molecular markers) carried by the newly added bases. The sequencing platform for this patient was Illumina. The results of next-generation sequencing of tumor tissues revealed SMARCA4 gene mutations with two pathogenic variants: (1) SMARCA4: NM_001128844.1: 7 / 36: c.939_940insT: p. (Ala314Cysfs*73); (2) SMARCA4: NM_001128844.1: 20 / 36: c.2631C>A: p. (Tyr877*), such as Figure 3 .

[0072] Because the patient's tumor had characteristic gene mutations, this provided a good criterion for identifying the extracted primary cell line as SCCOHT tumor cells. The cell line was then verified by Sanger sequencing, and the results showed that the cell line had two SMARCA4 mutations of the patient, proving that the extracted cells were tumor cells.

[0073] Example 5 Verification of SCCOHT tumor characteristic protein expression

[0074] Immunohistochemical staining: Monoclonal SCCOHT-CH-1 cells were fixed with 4% formaldehyde solution, embedded in paraffin and sliced. The slices were routinely dewaxed with xylene and hydrated with ethanol. Sodium citrate buffer (pH 6.0) was added and heated at 95°C for 12 minutes, and then slowly cooled to room temperature. 0.3% H2O2-methanol solution was used for incubation at 37°C for 15 minutes, and 10% bovine serum albumin solution was added for blocking for 60 minutes. Diluted primary antibodies (SMARCA4, SMARCB1) were added and incubated at 4°C overnight. HRP-labeled secondary antibodies were added and incubated at 37°C for 90 minutes. After DAB color development for 1 to 5 minutes, the reaction was terminated by rinsing with tap water for 15 minutes, and then hematoxylin counterstaining, dehydration, permeabilization, and sealing were performed in sequence. TBS was used to replace the primary antibody as a negative control.

[0075] Normal ovarian epithelial cell line IOSE80 (expressing SMARCA4 and SMARCB1 proteins) and SCCOHT cell line COV434 (SMARCA4 deletion and SMARCB1 expression) were selected as controls. The results showed that SCCOHT-CH-1 SMARCA4 expression was deleted and SMARCB1 expression was normal, further confirming that it was a SCCOHT tumor cell line. Figure 4 .

[0076] Example 6 Animal model of ovarian hypercalcemia small cell carcinoma cell line SCCOHT-CH-1 and its construction method

[0077] The method for constructing an animal model of ovarian hypercalcemia small cell carcinoma cell line SCCOHT-CH-1 comprises the following steps:

[0078] 1) Prepare a 10 cm dish of SCCOHT-CH-1 cells (approximately 1×10 7 indivual);

[0079] 2) After the cells have grown to full size, trypsin is used to digest and collect the cells, and each dish of cells is resuspended in 100ul PBS buffer;

[0080] 3) Grab and fix the mouse, insert the syringe parallel to the back of the mouse, and inject 100ul at each site;

[0081] 4) Slowly rotate and pull out the syringe, put the mouse back into the cage and continue to raise it. Tumors can be seen after 2 weeks.

[0082] According to the above method, an animal model of ovarian hypercalcemia small cell carcinoma cell line SCCOHT-CH-1 was obtained. Figure 5 .

[0083] Example 7 Drug Screening Experiment

[0084] CCK8 kit (Dojin Chemical Research Institute, Japan) was used to detect the drug sensitivity of SCCOHT-CH-1 cells.

[0085] The specific experimental steps are as follows:

[0086] 1. Preparation of cell suspension: Digest and count the cells. Use culture medium containing 10% fetal calf serum to prepare a single cell suspension of 20,000 cells / ml;

[0087] 2. Cell inoculation: Before inoculation, add 100 μl of PBS to each of the 36 wells around the 96-well plate, and inoculate 100 μl of cell suspension per well into the 96-well plate. Shake well and place in the incubator. Set up 8 concentration gradients, and set up 6 replicate wells for each concentration gradient;

[0088] 3. Drug preparation: According to the drug instructions, the experimental drugs were prepared into different concentration gradients using cell culture medium: 50 μM, 5 μM, 500 nM, 50 nM, 5 nM, 0.5 nM, 0.05 nM, 0 nM;

[0089] 4. Drug treatment of cells: aspirate the culture medium and add 100 μl of culture medium containing different concentration gradients to each well;

[0090] 5. Treat cells with CCK8: After 48 hours, test cell viability. Prepare CCK8 reagent and culture medium at a ratio of 1:10 to a sufficient amount for the experiment. Aspirate the original culture medium in the 96-well plate and add 100 microliters of CCK8 diluent. Try to avoid bubbles in the operating room. Add 100 microliters of CCK8 diluent to the blank well without cells as a blank control. Incubate in the incubator for 1 to 2 hours;

[0091] 6. Measure the OD value with an enzyme-labeled instrument and set the absorbance at 450 nm according to the instructions.

[0092] Screening test results, such as Figure 6 .

[0093] The above examples are for the purpose of illustrating the embodiments disclosed by the present invention and are not to be construed as limiting the present invention. In addition, the various modifications listed herein and the variations of the methods in the invention are obvious to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications as described above that are obvious to those skilled in the art to obtain the invention should be included within the scope of the present invention.

Claims

1. A human ovarian hypercalcemic small cell carcinoma cell line SCCOHT-CH-1, characterized in that: The deposit number is CGMCC No.45243.

2. Asexually propagated progeny cells of the ovarian hypercalcemic small cell carcinoma cell line SCCOHT-CH-1 according to claim 1.

3. A method for constructing an animal model of ovarian hypercalcemia-type small cell carcinoma, characterized in that: The cells of the ovarian hypercalcemia-type small cell carcinoma cell line according to claim 1 are inoculated into a model animal.

4. Use of the ovarian hypercalcemic small cell carcinoma cell line SCCOHT-CH-1 according to claim 1 or the ovarian hypercalcemic small cell carcinoma animal model constructed according to the method of claim 3 in developing targets for tumor therapeutic products or in screening tumor therapeutic products.

5. Use of the ovarian hypercalcemic small cell carcinoma cell line SCCOHT-CH-1 according to claim 1 or the ovarian hypercalcemic small cell carcinoma animal model constructed according to the method of claim 3 in screening biomarkers for ovarian hypercalcemic small cell carcinoma or studying the occurrence and development mechanism of ovarian hypercalcemic small cell carcinoma.